Get the Stockscreener App
1.05
1.94%
0.02
Pre-market:
1.06
0.01
+0.95%
Cardiol Therapeutics Inc stock is traded at $1.05, with a volume of 249.38K.
It is up +1.94% in the last 24 hours and down -20.45% over the past month.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
See More
Previous Close:
$1.03
Open:
$1.03
24h Volume:
249.38K
Relative Volume:
0.38
Market Cap:
$121.04M
Revenue:
-
Net Income/Loss:
$-26.33M
P/E Ratio:
-3.7181
EPS:
-0.2824
Net Cash Flow:
$-17.65M
1W Performance:
-2.78%
1M Performance:
-20.45%
6M Performance:
+1.94%
1Y Performance:
-28.08%
1-Day Range:
$1.03
$1.0798
1-Week Range:
$1.025
$1.12
52-Week Range:
$0.88
$1.71
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.05 | 121.04M | 0 | -26.33M | -17.65M | -0.2824 |
TAK
Takeda Pharmaceutical Co Adr
|
15.77 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.07 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.69 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.95 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.57 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Initiated | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jun-26-24 | Initiated | ROTH MKM | Buy |
| Apr-22-24 | Initiated | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Stock (CRDL) Latest News
Why Cardiol Therapeutics Inc Class A stock is sliding today - Wealth Awesome
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Moderna to Present at Upcoming Conference in June 2026 - Investing News Network
CRDL Q1 2026 Earnings: Narrower-than-Expected Loss Signals Cost DisciplineConsensus Miss Rate - newsline.com
Cardiol Therapeutics (CRDL) Dips 4.7% as Shares Test Key Support LevelsWave Truncation - The Legal Advocate
Cardiol Therapeutics Sets June 24, 2026 Virtual AGM and Adopts Notice-and-Access for Proxy Materials - TipRanks
Cardiol Therapeutics (Nasdaq: CRDL) outlines 2026 virtual shareholder meeting - Stock Titan
Cardiol Therapeutics Inc. (CRDL) Modestly Advances as It Holds Above Key SupportStop Hunt - The Legal Advocate
Cardiol Therapeutics Inc CRDL Modestly Advances as It Holds Above Key SupportThe Legal Advocate - The Legal Advocate
CRDL Q4 2025 Earnings: Narrower Loss Surpasses Estimates Amid Clinical ProgressSurprise Factor Analysis - newsline.com
CRDL Q4 2025 Earnings: Loss Narrows as EPS Beats Estimates by 14.2%Financial Data - newsline.com
CRDL Q4 2025 Earnings: Narrower Than Expected Loss as Cardiol Therapeutics Advances Clinical PipelineEPS Revision Trend - newsline.com
CRDL Stock Chart | CARDIOL THERAPEUTICS INC-A (NASDAQ:CRDL) - ChartMill
Cardiol Therapeutics Inc (TSX:CRDL) Stock Price & 30 Year Financial Data - GuruFocus
CCORF Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Maintains Target Price $8 - Moomoo
CRDL News | CARDIOL THERAPEUTICS INC-A (NASDAQ:CRDL) - ChartMill
(CRDL) On The My Stocks Page (CRDL:CA) - Stock Traders Daily
[SCHEDULE 13G/A] Cardiol Therapeutics Inc. Amended Passive Investment Disclosure - Stock Titan
Here's Why We're Watching Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation - Yahoo Finance
Cardiol Therapeutics Inc.Class A Common Shares (NQ: CRDL - FinancialContent
Stocks in play: Cardiol Therapeutics Inc. - The Globe and Mail
TradingKey - TradingKey
Cardiol Therapeutics to Present Pipeline at H.C. Wainwright BioConnect Conference at NASDAQ - TipRanks
Cardiol Therapeutics (CRDL) joins H.C. Wainwright BioConnect investor Fireside Chat at NASDAQ - Stock Titan
Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ - The Globe and Mail
Heart disease life sciences firm Cardiol joins Nasdaq investor chat - Stock Titan
H.C. Wainwright Maintains Cardiol Therapeutics(CRDL.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Cardiol Therapeutics Reports Higher Q1 2026 Loss but Stronger Cash Position - TipRanks
Cardiol Therapeutics (CRDL) extends cash runway and advances late-stage heart trials - Stock Titan
Cardiol Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Cardiol Therapeutics Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Cardiol Therapeutics’ Phase II MAvERIC Pericarditis Data Accepted by JAHA as Phase III Trial Nears Completion - TipRanks
Phase II MAvERIC data for CardiolRx in pericarditis to appear in JAHA for Cardiol (NASDAQ: CRDL) - Stock Titan
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association - PR Newswire
Cardiol Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
CRDL Stock Price, Quote & Chart | CARDIOL THERAPEUTICS INC-A (NASDAQ:CRDL) - ChartMill
CRDL.CA Stock Price, Quote & Chart | CARDIOL THERAPEUTICS INC-A (TSX:CRDL) - ChartMill
Phase III Trial Enrollment Reached (75%) for Promising Anti-Inflammatory and Anti-Fibrotic Cardiac Therapies by Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) - Barchart.com
Phase III Trial Enrollment Reached (75%) for Promising - openPR.com
User - The Chronicle-Journal
Ellis Martin Report: Cardiol Therapeutics (TSE.CRDL) CEO David Elsley on Breakthrough Heart Disease Treatment - ABN Newswire
Cardiol Therapeutics (CRDL) Expands MAVERIC Trial with New Clini - GuruFocus
Cardiol Therapeutics expands Phase III trial to 25 sites By Investing.com - Investing.com India
Cardiol Therapeutics expands Phase III trial to 25 sites - Investing.com UK
Cardiol Therapeutics Expands U.S. Phase III MAVERIC Trial Network as Enrollment Reaches 75% - TipRanks
Cardiol Therapeutics (NASDAQ: CRDL) expands U.S. MAVERIC Phase III trial network - Stock Titan
Cardiol Therapeutics Inc. Expands Maveric Phase III Trial Network and Provides Clinical Updates on Cardiolrx - marketscreener.com
Correction: Positive Results on MAVERIC Phase 2 and Published ARCHER Study Presented by the Company CEO in Live Interview with Barchart: Cardiol Therapeutics Inc. (NASDAQ: CRDL) - Barchart.com
Correction: Positive Results on MAVERIC Phase 2 and Published - openPR.com
Cardiol Therapeutics Inc Stock (CRDL) Financials Data
Revenue
Net Income
Cash Flow
EPS
9.24%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):